Micah Benson

Company: KSQ Therapeautics

Job title: Chief Scientific Officer

Seminars:

eTIL: Enhancing Anti-Tumor Function through CRISPR/Cas9 Gene Editing 11:00 am

Immune CRISPRomics Platform discovered SOCS1 and Regnase-1 as top gene targets enhancing T-cell anti-tumor function KSQ-001EX and KSQ-004EX are single and dual-edited engineered TIL (eTIL) products with inactivation of SOCS1 and Regnase-1Read more

day: Conference Day One - Track A - AM

Industry Leaders Fireside Chat: Challenges & Opportunities in Expanding Beyond Melanoma 8:30 am

What is the current state on developing TILs for indications beyond melanoma? What are key hurdles that must be overcome to apply TILs to more diverse indications? How do we evaluate what indications are most suitable to target with TILs? What are some key opportunities and breakthroughs in applying TILs to uncharted indications?Read more

day: Conference Day One